Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Iuliani

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Frontiers in Oncology|June 26, 2020
Current and Emerging Biomarkers Predicting Bone Metastasis DevelopmentMichele Iuliani, Sonia Simonetti, Giulia Ribelli, et al.
Journal of Hematology & Oncology|September 19, 2012
Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jawBruno Vincenzi, Andrea Napolitano, Alice Zoccoli, et al.
Cancers|September 1, 2019
Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical OverviewAntonella Argentiero, Antonio Giovanni Solimando, Oronzo Brunetti, et al.
Journal for Immunotherapy of Cancer|June 22, 2024
Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC)Michele Iuliani, Sonia Simonetti, Leonardo Cristofani, et al.
Biology|August 27, 2021
Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell CarcinomaMichele Iuliani, Sonia Simonetti, Francesco Pantano, et al.
Scientific Reports|January 30, 2020
Dynamic changes of Receptor activator of nuclear factor-κB expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast CancerFrancesco Pantano, Elisabetta Rossi, Michele Iuliani, et al.
Expert Opinion on Therapeutic Targets|March 27, 2012
Premetastatic niche: ready for new therapeutic interventions?Alice Zoccoli, Michele Iuliani, Francesco Pantano, et al.
Critical Reviews in Oncology/Hematology|November 8, 2017
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trialsSergio Rizzo, Antonio Galvano, Francesco Pantano, et al.
Critical Reviews in Oncology/Hematology|March 23, 2017
Determinants of bone specific metastasis in prostate cancerPaolo Manca, Francesco Pantano, Michele Iuliani, et al.
International Journal of Molecular Sciences|March 10, 2022
Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone MicroenvironmentMichele Iuliani, Sonia Simonetti, Giulia Ribelli, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Frontiers in Oncology|June 26, 2020
Current and Emerging Biomarkers Predicting Bone Metastasis DevelopmentMichele Iuliani, Sonia Simonetti, Giulia Ribelli, et al.
Journal of Hematology & Oncology|September 19, 2012
Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jawBruno Vincenzi, Andrea Napolitano, Alice Zoccoli, et al.
Cancers|September 1, 2019
Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical OverviewAntonella Argentiero, Antonio Giovanni Solimando, Oronzo Brunetti, et al.
Journal for Immunotherapy of Cancer|June 22, 2024
Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC)Michele Iuliani, Sonia Simonetti, Leonardo Cristofani, et al.
Biology|August 27, 2021
Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell CarcinomaMichele Iuliani, Sonia Simonetti, Francesco Pantano, et al.
Scientific Reports|January 30, 2020
Dynamic changes of Receptor activator of nuclear factor-κB expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast CancerFrancesco Pantano, Elisabetta Rossi, Michele Iuliani, et al.
Expert Opinion on Therapeutic Targets|March 27, 2012
Premetastatic niche: ready for new therapeutic interventions?Alice Zoccoli, Michele Iuliani, Francesco Pantano, et al.
Critical Reviews in Oncology/Hematology|November 8, 2017
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trialsSergio Rizzo, Antonio Galvano, Francesco Pantano, et al.
Critical Reviews in Oncology/Hematology|March 23, 2017
Determinants of bone specific metastasis in prostate cancerPaolo Manca, Francesco Pantano, Michele Iuliani, et al.
International Journal of Molecular Sciences|March 10, 2022
Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone MicroenvironmentMichele Iuliani, Sonia Simonetti, Giulia Ribelli, et al.
Pageof 5